These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 19450059

  • 1. Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.
    Vekeman F, McKenzie RS, Bookhart BK, Laliberté F, Duh MS, Tak Piech C, Lefebvre P.
    J Med Econ; 2009 Mar; 12(1):1-8. PubMed ID: 19450059
    [Abstract] [Full Text] [Related]

  • 2. Propensity score matched assessment of treatment patterns and cost of erythropoiesis stimulating agent treatment in patients with cancer receiving myelosuppressive chemotherapy.
    Tunceli O, Bailey RA, Stephenson JJ, Singer J.
    J Oncol Pharm Pract; 2013 Dec; 19(4):305-14. PubMed ID: 23235918
    [Abstract] [Full Text] [Related]

  • 3. Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.
    Duh MS, Mody SH, Scott McKenzie R, Lefebvre P, Gosselin A, Tak Piech C.
    Clin Ther; 2006 Sep; 28(9):1443-50. PubMed ID: 17062316
    [Abstract] [Full Text] [Related]

  • 4. Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations.
    Lefebvre P, Gosselin A, McKenzie RS, Mody SH, Piech CT, Duh MS.
    Curr Med Res Opin; 2006 Sep; 22(9):1623-31. PubMed ID: 16968565
    [Abstract] [Full Text] [Related]

  • 5. Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.
    Lafeuille MH, Bailey RA, Vekeman F, Scott McKenzie R, Lefebvre P.
    J Med Econ; 2012 Sep; 15(2):352-60. PubMed ID: 22168787
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in anemic predialysis chronic kidney disease patients from an observational study.
    Papatheofanis F, Smith C, Mody S, McKenzie RS, Bookhart B, Piech CT.
    Am J Ther; 2007 Sep; 14(4):322-7. PubMed ID: 17667204
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cost analysis of erythropoietic-stimulating therapy dosing in oncology inpatients.
    Killian AD, Gupta V, Goetz AE.
    Ann Pharmacother; 2006 Mar; 40(3):421-6. PubMed ID: 16507613
    [Abstract] [Full Text] [Related]

  • 10. The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.
    Ben-Hamadi R, Duh MS, Aggarwal J, Henckler A, McKenzie RS, Tak Piech C.
    Curr Med Res Opin; 2005 Oct; 21(10):1677-82. PubMed ID: 16238908
    [Abstract] [Full Text] [Related]

  • 11. Health economic evaluation of treating anemia in cancer patients receiving chemotherapy: a study in Belgian hospitals.
    Spaepen E, Demarteau N, Van Belle S, Annemans L.
    Oncologist; 2008 May; 13(5):596-607. PubMed ID: 18515745
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia.
    Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.
    Support Care Cancer; 2012 Jan; 20(1):159-65. PubMed ID: 21359879
    [Abstract] [Full Text] [Related]

  • 14. The impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.
    Song X, Long SR, Marder WD, Sullivan SD, Kallich J.
    Ann Pharmacother; 2009 Jul; 43(7):1203-10. PubMed ID: 19584392
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
    Nurko S, Spirko R, Law A, Dennis VW.
    Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
    [Abstract] [Full Text] [Related]

  • 17. Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa.
    Hymes J, Bickimer T, Jackson JH, Bookhart BK, Mody SH, Tak Piech C.
    Curr Med Res Opin; 2007 Aug; 23(8):1931-7. PubMed ID: 17624232
    [Abstract] [Full Text] [Related]

  • 18. Use of darbepoetin alfa and epoetin alfa in clinical practice in patients with cancer-related anemia.
    Berger A, Edelsberg J, Kallich J, Oster G.
    Clin Ther; 2008 Jan; 30(1):206-18. PubMed ID: 18343258
    [Abstract] [Full Text] [Related]

  • 19. Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen.
    Sikand H, Decter A, Greco T, Watson SH, Kang YJ, Mody SH, Piech CT, Duh MS, Naeem A.
    Ann Pharmacother; 2008 Jan; 42(1):16-23. PubMed ID: 18029428
    [Abstract] [Full Text] [Related]

  • 20. Retrospective observational study of patients with chemotherapy-related anemia receiving erythropoietic agents.
    Mark TL, McKenzie RS, Fastenau J, Piech CT.
    Curr Med Res Opin; 2005 Sep; 21(9):1347-54. PubMed ID: 16197652
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.